Daclizumab biosimilar (Shanghai CP Guojian) | Interleukin Related interleukin-related.com

Product Name :
Daclizumab biosimilar (Shanghai CP Guojian)

Search keywords :
IL-2

drugId :
null

Target Vo:
Interleukin-2 receptor alpha chain

Target Vo Short Name :
IL2RA

Moa_Name:
Interleukin-2 receptor alpha chain inhibitors

First Approval Country :
Mainland China

First Approval Date Filter:
2011

Origin Company_Name :
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd

Active Company_Name :

Active Indication_Name:
Rejection of renal transplantation

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Cofetuzumab pelidotin Purity & Documentation
Tozorakimab References
SIRT3 Antibody: SIRT3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 44 kDa, targeting to SIRT3. It can be used for WB,IHC-P assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts